Publications
Learn about the research supporting our preclinical and clinical development programs.

Publications

Learn about the research supporting our preclinical and clinical development programs.

Publications

November 2, 2021
Journal for ImmunoTherapy of Cancer
BT7480, a Novel Fully Synthetic Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Induces Tumor Localized CD137 Agonism
January 26, 2021
Journal for ImmunoTherapy of Cancer
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist
August 18, 2020
ACS Infectious Diseases
An Assay for Periplasm Entry Advances the Development of Chimeric Peptide Antibiotics
May 12, 2020
Molecular Cancer Therapeutics
MMAE delivery using the Bicycle toxin conjugate BT5528
March 30, 2020
Journal of Medicinal Chemistry
Identification and Optimization of EphA2-Selective Bicycles for Delivery of Cytotoxic Payloads
February 15, 2019
AACR Journals
Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors
June 6, 2018
ADMET
Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics
March 8, 2018
Journal of Medicinal Chemistry
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema
July 1, 2012
ChemMedChem
Bicyclic Peptides with Optimized Ring Size Inhibit Human Plasma Kallikrein and its Orthologues While Sparing Paralogous Proteases
May 31, 2009
Nature Chem Bio
Phage-encoded combinatorial chemical libraries based on bicyclic peptides

Presentations

EuroTIDES – November 2021

November 19, 2021
Bicycles, bi-cyclic peptides, novel small molecule delivery systems for RNA therapeutics
Presentation
Video

SITC

November 12, 2021
Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)
November 12, 2021
Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)
November 12, 2021
An integrative approach to optimize a synthetic EphA2-dependent CD137 agonist: Balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity
November 12, 2021
Generation of a Bicycle NK-TICA™, a novel NK cell engaging molecule designed to induce targeted tumor cytotoxicity

AACR-NCI-EORTC

October 7, 2021
A first in class phase I/II study of the novel bicyclic peptide and MMAE conjugate, BT5528, in patients with advanced malignancies associated with EphA2 expression

ASCO

June 4, 2021
A Combined Phase I/II Study of BT8009 a Novel Bicycle® Toxin Conjugate with MMAE in Patients with Advanced Malignancies with Nectin-4

AACR

April 12, 2021
BT7480, a novel Nectin-4 dependent agonist of the immune cell costimulatory receptor CD137
April 12, 2021
Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcoma and preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® toxin conjugate, in osteosarcoma by the Pediatric Preclinical Testing Consortium (PPTC)
April 10, 2021
Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009
April 10, 2021
Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle® tumor-targeted immune cell agonist (TICA™)
April 10, 2021
Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment
April 10, 2021
A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection
April 10, 2021
Rapid Accumulation of Cytotoxic Payload in Tumor Tissue Drives BT5528 Activity in Tumor Models

2020

2019

2018

2017